

Demystifying the Science Behind Targeted Treatments and Immunotherapies for Bowel Cancer

Virtual study day

Friday 9 July 2021

Event ID 856

Aims:

This morning's content builds on the virtual study day presented by Dr Vickers on 03 & 04 December: "Molecular mechanisms of targeted treatments and immunotherapies for solid tumours".

The aim of this course is to provide an up-to-date overview of modern systemic treatment approaches given to people with bowel cancer. Including treatment combinations and new approaches currently being investigated in clinical trials.

Dr Vickers' goal is to explain the science that underpins each treatment. She also hopes to provide learners with a broad understanding of why treatments work well for some patients but not for others.

Elaine's presentations are full of colourful and enlightening illustrations to help learners make sense of scientific concepts. Her descriptions avoid unnecessary jargon and are pitched so that even those with a limited understanding of cell biology are able to understand.

Audience:

This content is ideal for research nurses, clinical nurse specialists, pharmacists and clinical trials coordinators. It may also be of interest to other healthcare professionals involved in the diagnosis and treatment of people with solid tumours, and to junior doctors.

Cost:

£50 per delegate

Register:

www.royalmarsden.nhs.uk/studydays

Get in touch:

Conferenceteam@rmh.nhs.uk

020 7808 2921

Follow us:



Programme

- 10:00** **Welcome and Introductions**
- 10:10** **Session 1—Biology and genetics of bowel cancer**
- Cell of origin and mechanisms of development
 - Key genetic mutations and defective pathways and proteins in bowel cancer cells
 - Recent classification systems and what they mean
 - Explaining the relationship between mismatch repair deficiency and microsatellite instability
- 10:45** **Live Q&A**
- 10:55** **Break/Sponsor Exhibition**
- 11:00** **Session 2—Monoclonal antibodies targeting EGFR**
- Refresher of growth factor receptor signalling pathways and the normal functions of EGF receptors
 - Licensed EGFR inhibitors; summary of pivotal trials
 - Further exploration of trial data – comprehensive RAS mutation testing; left vs right bowel cancers
 - Resistance mechanisms to EGFR- targeted antibodies
 - Current trials
- 11:35** **Live Q&A**
- 11:45** **Break/Sponsor Exhibition**
- 11:50** **Session 3—Other systemic treatments**
- Angiogenesis inhibitors
 - Checkpoint inhibitors as treatments for bowel cancer – trial data in MMR-deficient and MMR-proficient cancers
 - B-Raf inhibitor combinations
 - Targeting HER2 and mutated Ras proteins
 - Other systemic treatment approaches in trials
- 12:25** **Live Q&A**

Please note that the content will be available for 30 days after the event online.

Sponsors:



Pierre Fabre

The above sponsors provided funding for the study day, but they have had no input into the programme, selection of speakers or topics.